Cite
HARVARD Citation
Stutterheim, J. et al. (2022). Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol. European journal of cancer. pp. 72-79. [Online].